Ghent University Academic Bibliography

Your filters: cql: author="Hallberg, Bengt" or (type any "bookEditor issueEditor" and editor="Hallberg, Bengt")

Add to list
- Journal Article
- A2
- open access
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN

Jonatan Linus Gabre (UGent) , Peter Merseburger (UGent) , Arne Claeys (UGent) , Joachim Siaw (UGent) , Sarah-Lee Bekaert (UGent) , Franki Speleman (UGent) , Bengt Hallberg, Ruth H Palmer and Jimmy Van den Eynden (UGent)

(2024) NAR CANCER. 6(1).
Add to list
- Journal Article
- A1
- open access
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition

Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, Wei-Yun Lai, Jikui Guan, Joel Johansson, Eva Jennische, Alexander Schmidt, Yeshwant Kurhe, Jonatan Linus Gabre (UGent) , et al.

(2024) PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 121(1).
Add to list
- Journal Article
- A1
- open access
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression

Tzu-Po Chuang, Wei-Yun Lai, Jonatan Linus Gabre (UGent) , Dan E. Lind, Ganesh Umapathy, Abdulmalik A. Bokhari, Bengt Bergman, Linnea Kristenson, Fredrik B. Thorén, Anh Le, et al.

(2023) PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 120(8).
Add to list
- Journal Article
- A1
- open access
Loss of RET promotes mesenchymal identity in neuroblastoma cells

Joachim T. Siaw, Jonatan Linus Gabre (UGent) , Ezgi Uçkun, Marc Vigny, Wancun Zhang, Jimmy Van den Eynden (UGent) , Bengt Hallberg, Ruth H. Palmer and Jikui Guan

(2021) CANCERS. 13(8).
Add to list
- Journal Article
- A1
- open access
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim Tetteh Siaw, Arne Claeys (UGent) , Jonatan Linus Gabre (UGent) , Jimmy Van den Eynden (UGent) , Bengt Hallberg, et al.

(2021) NATURE COMMUNICATIONS. 12(1).
Add to list
- Journal Article
- A1
- open access
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Marcus Borenäs, Ganesh Umapathy, Wei‐Yun Lai, Dan E Lind, Barbara Witek, Jikui Guan, Patricia Mendoza‐Garcia, Tafheem Masudi, Arne Claeys (UGent) , Tzu‐Po Chuang, et al.

(2021) EMBO JOURNAL. 40(3).
Add to list
- Journal Article
- A1
- open access
11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma

Joachim Tetteh Siaw, Niloufar Javanmardi, Jimmy Van den Eynden (UGent) , Dan Emil Lind, Susanne Fransson, Angela Martinez-Monleon, Anna Djos, Rose-Marie Sjöberg, Malin Östensson, Helena Carén, et al.

(2020) CELL REPORTS. 32(12).
Add to list
- Journal Article
- A1
- open access
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Liselot Mus (UGent) , Irina Lambertz (UGent) , Shana Claeys (UGent) , Candy Kumps (UGent) , Wouter Van Loocke (UGent) , Christophe Van Neste (UGent) , Ganesh Umapathy, Marica Vaapil, Christoph Bartenhagen, Genevieve Laureys (UGent) , et al.

(2020) SCIENTIFIC REPORTS. 10.
Add to list
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

Jimmy Van den Eynden (UGent) , Ganesh Umapathy, Arghavan Ashouri, Diana Cervantes-Madrid, Joanna Szydzik, Kristina Ruuth, Jan Koster, Erik Larsson, Jikui Guan, Ruth H Palmer, et al.

(2018) SCIENCE SIGNALING. 11(557).
Add to list
- Journal Article
- A2
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Jikui Guan, Susanne Fransson, Joachim Tetteh Siaw, Diana Treis, Jimmy Van den Eynden (UGent) , Damini Chand, Ganesh Umapathy, Kristina Ruuth, Petter Svenberg, Sandra Wessman, et al.

(2018) COLD SPRING HARBOR MOLECULAR CASE STUDIES. 4(4).

Academic Bibliography

Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN

ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition

ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression

Loss of RET promotes mesenchymal identity in neuroblastoma cells

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Contents

Support

Contact